5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Feasibility of Long-Term Closed-Loop Control: A Multicenter 6-Month Trial of 24/7 Automated Insulin Delivery.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In the past few years, the artificial pancreas-the commonly accepted term for closed-loop control (CLC) of blood glucose in diabetes-has become a hot topic in research and technology development. In the summer of 2014, we initiated a 6-month trial evaluating the safety of 24/7 CLC during free-living conditions.

          Related collections

          Author and article information

          Journal
          Diabetes Technol. Ther.
          Diabetes technology & therapeutics
          Mary Ann Liebert Inc
          1557-8593
          1520-9156
          Jan 2017
          : 19
          : 1
          Affiliations
          [1 ] 1 University of Virginia Center for Diabetes Technology, Charlottesville, Virginia.
          [2 ] 2 Jaeb Center for Health Research , Tampa, Florida.
          [3 ] 3 William Sansum Diabetes Center , Santa Barbara, California.
          [4 ] 4 University of Padova , Padova, Italy .
          [5 ] 5 Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Stanford University School of Medicine , Stanford, California.
          [6 ] 6 Department of Chemical Engineering, University of California , Santa Barbara, Santa Barbara, California.
          [7 ] 7 Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University , Cambridge, Massachusetts.
          Article
          10.1089/dia.2016.0333
          27982707
          902e99d9-a6e2-4435-8a2b-89adfad0bac7
          History

          Artificial pancreas.,Automated insulin delivery (AID),Closed-loop control,Continuous glucose monitoring (CGM),Insulin pump therapy

          Comments

          Comment on this article